AI-Accelerated Nonclinical Drug Testing Market

The machine learning platforms segment leads the AI-accelerated nonclinical drug testing market by technology with a 30.5% share in 2026. Toxicity prediction accounts for 31.4% by application, pharmaceutical companies hold 33.5% by end user, and in silico testing represents 39.0% by test type.